Kay Olmstead
Directeur/Bestuurslid bij BENO TNR, INC.
Profiel
Kay Olmstead is the founder and current CEO & Director of Nano PharmaSolutions, Inc., a company founded in 2019.
She is also currently a Director at BENO TNR, Inc.
Actieve functies van Kay Olmstead
Bedrijven | Functie | Begin |
---|---|---|
BENO TNR, INC. | Directeur/Bestuurslid | - |
Nano Pharmasolutions, Inc.
Nano Pharmasolutions, Inc. Pharmaceuticals: MajorHealth Technology Nano Pharmasolutions, Inc. is a pharmaceutical company based in an undisclosed location. Nano Pharmasolutions is developing a dry powder for inhalation (DPI) formulation of remedesivir to fight COVID-19. The American company's platform is based on physical vapor deposition (PVD) technology, which allows them to make drug nanoparticles with no excipients or solvents. These nanodrug particles can be used in various forms such as pills, nasal sprays, creams/salves, inhalers, and eye drops. The private company's nanotransformer™ technology can create an e-8 torr vacuum, and it uses carrier solids selected from hydrophilic pharmaceutical excipients to deposit vapor phase drugs as nanoparticles on fast-moving carriers. The company was founded by Kay Olmstead, Saeyeon Lee, Seok-Keun Koh, and Kay Olmstead has been the CEO since incorporation. | Oprichter | 01-06-2019 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BENO TNR, INC. | Technology Services |
Bedrijven in privébezit | 1 |
---|---|
Nano Pharmasolutions, Inc.
Nano Pharmasolutions, Inc. Pharmaceuticals: MajorHealth Technology Nano Pharmasolutions, Inc. is a pharmaceutical company based in an undisclosed location. Nano Pharmasolutions is developing a dry powder for inhalation (DPI) formulation of remedesivir to fight COVID-19. The American company's platform is based on physical vapor deposition (PVD) technology, which allows them to make drug nanoparticles with no excipients or solvents. These nanodrug particles can be used in various forms such as pills, nasal sprays, creams/salves, inhalers, and eye drops. The private company's nanotransformer™ technology can create an e-8 torr vacuum, and it uses carrier solids selected from hydrophilic pharmaceutical excipients to deposit vapor phase drugs as nanoparticles on fast-moving carriers. The company was founded by Kay Olmstead, Saeyeon Lee, Seok-Keun Koh, and Kay Olmstead has been the CEO since incorporation. | Health Technology |